How Sweet is it? Measurement of Glucose in Epidural and Spinal Fluid
NCT ID: NCT01391702
Last Updated: 2012-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
65 participants
OBSERVATIONAL
2011-06-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that a bedside glucose measurement device can accurately quantitate the level of glucose within epidural space aspirate, and therefore could aid differentiation between CSF and epidural fluid.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measuring Cerebrospinal Fluid (CSF) Glucose Levels in Patients Under Going an Elective Cesarean Section With Spinal Anesthesia
NCT01067560
Fluid Management for Cesarean Section II
NCT00973791
Ultrasound Guidance for Epidural Analgesia and Anesthesia
NCT02436109
Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section
NCT02036697
The Effect of Administering a Small Dose of Glucose During Cesarean Section
NCT01706341
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When a cesarean delivery is required following a trial of labour, an epidural catheter in situ can be used to provide surgical anesthesia. A large volume (10-20 milliliters) of local anesthetic is administered through the epidural catheter. This is aimed to produce a dense nerve block up to T4 (nipple level), which is sufficient for lower abdominal surgery.
Occasionally, however, this technique does not provide adequate anesthesia for a surgical intervention - termed a 'failed epidural top-up' - and this is estimated to occur up to 38% of the time. Options following the failure of an epidural top-up are dependent on the urgency of delivery, and include either a general anesthetic or an intrathecal injection of local anesthetic (a 'spinal'). The preferred choice for both mother and baby, if time allows, is normally considered to be a spinal.
A spinal is performed by inserting a needle into the subarachnoid space which is surrounded by the epidural space. The subarachnoid space contains CSF, the spinal cord and exiting nerves from the spinal cord. The anesthesiologist identifies the subarachnoid space by obtaining CSF through the needle. Local anesthetic can then be injected directly into the space.
Rarely, spinal anesthesia may fail when administered following a failed epidural, and there are several theories as to why this may occur.
One possible reason for spinal failure is that the large volume of local anesthetic, which is injected down the epidural catheter for cesarean delivery anesthesia, can cause the subarachnoid space to collapse, making it difficult to access with a needle and obtain CSF.
Another theory for failed spinal anesthesia involves misidentification of the clear fluid that returns through the spinal needle. It is postulated that in these circumstances the fluid seen is not CSF. It may be tissue fluid from the epidural space (transudate), local anesthetic that was injected into the epidural space or a combination of the two. In these cases, the needle is not in the subarachnoid space and, therefore, spinal anesthesia will fail.
Anatomical variations, such as a congenital arachnoid cyst, may also contribute to failed spinals following failed epidural top ups.
Various bedside tests have been described to confirm whether the fluid exiting the needle is CSF, including analyzing the fluid's temperature, density, pH, glucose content and whether it precipitated with thiopental (an alkaline solution). Whilst no single test has been completely effective, measurement of glucose seems to be the best indicator. Glucose is thought to be a good discriminator of the fluid obtained through a spinal because of the different proportions of glucose in the clear fluids which could return through the spinal needle. The level of glucose in the CSF is usually approximately 2/3 of plasma glucose (approximately 2-4mmol/L). There should be minimal glucose in the fluid drawn from the epidural space. However, a previous study has shown that a small amount of glucose may be present in the epidural space from 30 minutes after epidural catheter insertion. Potential sources of glucose in the epidural space may be blood, CSF or transudate.
In the past, the presence of glucose was done using a simple reagent strip, which is rapid (2 minutes) and accurate (when compared to laboratory values and testing), however, it solely detects either the presence or absence of glucose. As there may be a small amount of glucose present in the epidural space, the use of reagent strips may not distinguish between epidural fluid and CSF.
A glucose meter gives an absolute value for glucose, which may be more useful. Even though the epidural fluid may contain glucose, the absolute value would be significantly lower than that seen for CSF glucose. The range for normal CSF glucose in the parturient was confirmed using the bedside glucose meters in the Sweet CSF Study as 2-4 mmol/L. In this previous study we compared the efficacy, accuracy and ease of use of three glucose meters that were used to measure CSF glucose.1 The CSF glucose levels were compared to the results from the laboratory measurement of glucose. This study took place January - November, 2010 at BC Women's Hospital in Vancouver, British Columbia. The study established the feasibility of measuring CSF glucose measured with the three glucose meters, and for two meters, verified commonly accepted normal ranges in parturients having elective cesarean delivery under spinal anesthesia.
Now that we have obtained these values, we aim to see if the glucose levels of epidural space fluid (via an epidural catheter) differ from those of CSF using one of the previously tested bedside monitors. We also aim to distinguish the level of glucose in the fluid that returns through the needle if a spinal is done following a failed epidural.
Labouring women admitted to BC Women's will be assessed for eligibility for the study. Women who receive an epidural for labour analgesia will be approached by an investigator who will explain the project and answer questions about the study. Written information regarding the aims and practicalities of the study will be given to women. Informed consent will be obtained following the decision to proceed to cesarean delivery. Women will only be approached for consent to participate if there is time before their surgery. The study will not delay the surgery or interfere with routine standards of care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Labouring woman with epidural in situ
Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton pregnancy
* Age 19 years or older
* Understand written and oral English
Exclusion Criteria
19 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giselle Villar, MD, FRCPA
Role: PRINCIPAL_INVESTIGATOR
University of British Columbia, BC Women's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BC Women's Hospital
Vancouver, British Columbia, Canada
British Columbia's Women's Hospital
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H11-00901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.